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Functional differences between 
cultured osteoblasts and osteosarcoma 


























We have compared expression profiles of cultured primary osteoblasts and 
osteoblastic osteosarcoma cell lines by micro-array analysis in order to gain more 
insight into the molecular events underlying the development of osteosarcoma. A 
significantly different expression was found for 286 genes. For individual genes 
represented on the array by different oligonucleotides, results from the different pairs 
were concordant. Two genes with a significantly higher expression in the 
osteosarcoma cell lines and two genes with a significantly lower expression in the 
osteosarcoma cell lines were subjected to real-time RT-PCR analysis. The results 
confirmed those obtained by micro-array analysis. Functional annotation data 
revealed a lower expression in osteosarcoma cell lines of genes encoding proteins of 
the cell membrane and extracellular matrix and a higher expression of genes coding 
for nuclear proteins, such as cell cycle-related and DNA repair-associated proteins. 
In the osteosarcoma cell lines, an average lower expression was found for the MMP 
gene cluster at 11q22 and for the KAP gene cluster at 17q21.2. An average higher 
expression was found for the HOXB cluster at 17q21.3. Such co-expression of genes 
points to either chromosomal losses in tumours and tumour cell lines or to a common 
transcriptional regulation. The latter seems the more likely explanation for part of 
these findings.  




The progenitor of the most common type of osteosarcoma, osteoblastic 
osteosarcoma, representing about 40% of all bone tumours (Unni, 1998), is the 
osteoblast. Osteoblasts normally produce osteoid which by deposition of calcium can 
be converted into a mineralised hard matrix in which the non-dividing cells remain as 
osteocytes (Stains and Civitelli, 2003; Harada and Rodan, 2003).  
The genetic alterations causing osteosarcoma development or contributing to it are 
largely unknown, although mutations have been found in several known cancer-
related genes, such as RB1, TP53, CDKN2A, CDKN2B, DCC, CDK4 and MDM2 
(Horstmann et al., 1997; Lohmann and Gallie, 2004; Park et al., 2004). TP53 and 
RB1 are the most frequently mutated genes in tumours in general, including 
osteosarcoma with percentages of 40% to 60% for TP53 and 50% to 70% for RB1 
(Hansen et al., 1985; Wadayama et al., 1994; Stock et al., 2000; Sandberg and 
Bridge, 2003; Overholtzer et al., 2003; van Dartel et al., 2004). Less frequently 
mutated in osteosarcoma are CDKN2A and CDKN2B with percentages of 5% to 10% 
(Miller et al., 1996a;Tsuchiya et al., 2000). Since, these genes have mutations in up 
to 60% of osteosarcoma cell lines, they probably have a role in tumour cell growth in 
culture (Miller et al., 1996). DCC seems to be frequently mutated in osteosarcoma 
(50% to 70%), but only a small number of tumours have been analysed (Horstmann 
et al., 1997). Less frequently in primary osteosarcoma, but more frequently in 
recurrent or metastatic osteosarcoma, MDM2 is mutated with frequencies that range 
from 4% to 27% (Oliner et al., 1992; Park et al., 2004). 
Furthermore, cytogenetic analysis and analysis by comparative genomic 
hybridisation have shown frequent chromosomal involvement of 1p, 2q, 3q, 6p, 8q, 
10, 13q, 15q, 17p, 18q and 20 (Squire et al., 2003; Lau et al., 2004; Man et al., 
2004), indicating that these chromosomal regions may contain genes involved in the 
development of osteosarcoma.  
We have previously used gene expression profiling of primary unstimulated 
osteoblasts as a fast and efficient test to characterise these cells and discriminate 
them from fibroblasts (M. Wilkens, K.A. Kooi, E.A.D. Plantinga, G.J. te Meerman, 
R.M.W. Hofstra, C.H.C.M. Buys, F. Gerbens, submitted). Here we compare gene 
expression profiles of cultured osteoblasts with those of osteosarcoma cell lines to 




Material & Methods 
 
Patient and cell line material 
 
Four females and one male undergoing surgery for a total knee replacement at ages 
ranging from 57 to 84 were included in this study as donors of trabecular bone 
fragments. All samples were collected fully anonymously and used in accordance 
with the ethical regulations of the hospital.  
Five human osteoblastic osteocarcoma cell lines namely MG63 (ATCC CRL-1427), 
SaOS-2 (ATCC-HTB-85), HOS (ATCC CRL-1543), U-2 OS (ATCC-HTB-96) and 
G292 (ATCC-CRL-1423) obtained from the American Type Culture Collection 
(ATCC, Baltimore, MD, USA) were included in this study.  
 
Culturing of primary osteoblasts and osteosarcoma cell lines 
 
Trabecular bone fragments were treated as described by Scheven et al. (1991) to 
obtain primary osteoblastic cells. Specimens were transported under sterile 
conditions from the operating centre to the laboratory, chopped into pieces of 0.2 cm 
– 1.0 cm in diameter and washed three times with sterile phosphate-buffered saline. 
Bone fragments were treated with collagenase (1 mg/ml) (GIBCO - Invitrogen Inc, 
Carlsbad, Ca, USA) at 37°C during 2.5 h and again washed three times with sterile 
phosphate-buffered saline. Subsequently, the bone fragments were cultured in 
Dulbecco‘s modified Eagle medium (DMEM) with l-glutamax (GIBCO - Invitrogen) 
supplemented with 100 IU/ml penicillin and 1000 µg/ml streptomycin (all from GIBCO 
- Invitrogen) and 10% foetal bovine serum (Biowhittaker – Cambrex, Verviers, 
Belgium) in small culture flasks (25 cm2) at 37°C in a humidified atmosphere with 5% 
CO2. Cells isolated as osteoblasts were harvested for RNA isolation after reaching 
70% - 80% of confluence by trypsin (0.05%)/EDTA (0.02%) (GIBCO – Invitrogen) 
treatment, pelleted, washed with sterile phosphate-buffered saline, pelleted again 
and stored at –80°C until RNA isolation. Characterisation of the isolated osteoblasts 
was performed by comparison to fibroblasts through real-time RT-PCR analysis of six 
tissue-specific genes (M. Wilkens, K.A. Kooi, E.A.D. Plantinga, G.J. te Meerman, 
R.M.W. Hofstra, C.H.C.M. Buys, F. Gerbens, submitted). 
The human osteoblastic osteosarcoma cell lines MG63, SaOS-2 and HOS were 
cultured on RPMI1640 (GIBCO – Invitrogen), while U-2 OS and G292 were grown on 
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McCoy’s 5A (GIBCO - Invitrogen). Both media were supplemented with 10% foetal 
bovine serum (Biowhittaker), 2 mM glutamine, 100 U/ml penicillin, 1000 µg/ml 
streptomycin and 250 µg/ml fungizone amphotericine B (all from GIBCO - Invitrogen). 
All cell lines were cultured in culture flasks at 37°C in a humidified atmosphere with 
5% CO2. After having reached 70% to 80% of confluence, human osteosarcoma cells 
were harvested by trypsin (0.05%)/EDTA (0.02%) (GIBCO - Invitrogen) treatment, 
pelleted, washed with sterile phosphate-buffered saline, pelleted again and stored at 




Total RNA was isolated with the RNeasy mini kit (Qiagen, Valencia, CA, USA) and 
subsequently treated with DNase I (Qiagen) as described by the manufacturer. Total 
RNA yield and purity were calculated by measuring absorbances at 260 nm and 280 
nm spectrophotometrically on a NanoDrop® ND-1000 UV-VIS Spectrophotometer 
(Nanodrop technologies, Wilmington, DE, USA). RNA integrity was determined by 
1% formaldehyde agarose gel electrophoresis. 
 
mRNA Amplification and Cy-dye coupling 
 
Linear amplification of mRNA was performed essentially according to a protocol of 
the Dutch Cancer Institute (www.nki.l.nl/nkidep/pa/microarray/protocols.htm). Briefly, 
amplification started with first strand cDNA synthesis from 2 µg of total RNA, using 
Superscript II RT-polymerase (GIBCO - Invitrogen) and a specific oligo(dT) primer 
containing a 17bp T7 polymerase recognition site  
(5'-GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG[T]24-3')  
(Eurogentec, Seraing, Belgium). After second strand synthesis, double-stranded 
cDNA was purified with the Qiaquick PCR purification kit (Qiagen) and the yield was 
determined spectrophotometrically. In vitro transcription was performed with the T7 
Megascript kit (Ambion, Huntingdon-Cambridgeshire, UK) as described by the 
manufacturer, but using instead of UTP a 1:1 mixture of aminoallyl-UTP (Ambion) 
and UTP with a final concentration of 7.5 mM for all NTPs ('t Hoen et al., 2003). 
Amplified RNA (aRNA) was purified with the RNA clean up protocol (Qiagen). Five µg 
of aRNA was labelled by coupling monoreactive Cyanine 3 (2.5 nmol per reaction) or 
Cyanine 5 (2.5 nmol per reaction) fluorophores (Amersham Biosciences, Little 
Chalfont, Buckinghamshire, UK) to the aminoallyl-modified nucleotides. Labelled 
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aRNA was separated from unincorporated Cyanine 3 or Cyanine 5 molecules with 




The five primary osteoblast cultures and the five osteoblastic osteosarcoma cell lines 
were analysed as ten independent samples. Each sample was labelled with 
Cyanine-3 and Cyanine-5 separately and subsequently assigned at random to a 
sample of the opposite colour for hybridisation. 
 
Micro-array Slides & Hybridisation 
 
In-house manufactured human oligonucleotide arrays were used containing the 
Qiagen/Operon 21,329 70-mer human gene specific oligonucleotide set version 2.1 
extended with 4,000 negative and positive control features. The oligonucleotides 
were printed in a concentration of 10 pM on Ultra-GAPS amino-silane coated slides 
(Corning BV. Life Sciences, New York, USA) using BioRobotics 10K quill pins with 
the MicroGrid spotter (Isogen, Maarssen, The Netherlands). Blocking, 
prehybridisation and hybridisation were performed as described by Hegde et al 
(2000), with some modifications. In short, slides were blocked with ethanolamine at 
52°C during 1 h. Prehybridisation was done with prewarmed prehybridisation buffer 
containing 0.5% bovine serum albumin (Sigma - Aldrich, St. Louis, MO, USA) at 52°C 
during 45 min. Subsequently, the slides were washed 6 times with preheated water 
(52°C), dried by centrifugation at 800 rpm during 3 min and immediately used for 
hybridisation. The hybridisation sample consisted of the fluorescently labelled probe 
mixture and 30 µg poly-A (Sigma - Aldrich) mixed with an equal volume of preheated 
(52°C) 2X hybridisation buffer. This hybridisation sample was heated at 95°C for 3 
min before it was applied to the preheated slides. Hybridisation was performed in 
hybridisation chambers (Telechem International Inc, Sunnyvale, CA, USA) in a 
waterbath at 52°C in the dark for approximately 48 h. Subsequently, slides were 
washed with 5 wash solutions under agitation: 1xSSC/0.2% SDS at 52ºC; 
0.1xSSC/0.2% SDS at 52ºC; 0.1xSSC at 52ºC; 0.1xSSC at RT and 0.01xSSC at RT. 
Each wash step lasted 5 min. Finally slides were dried by centrifugation at 800 rpm 
during 3 min and scanned with an Affymetrix GMS428TM array scanner.  
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Micro-array data analysis 
 
Fluorescent signal intensity data for each spot and for each fluorophore were 
extracted from the scanned images of each micro-array slide using ImaGene version 
5.6 (BioDiscovery, El Segundo, California, USA). Signal intensity data were log 
transformed and for each spot the Cyanine-5 signal intensity/Cyanine-3 signal 
intensity ratio was determined and subjected to print-tip loess intensity dependent 
normalisation using the Limma package from the Bioconductor project in R 
(http://bioinf.wehi.edu.au/limma). Since no dependency exists between both samples 
during hybridisation ('t Hoen et al., 2004), normalised log-ratios were back 
transformed to log intensities. Further data analysis was performed using BRB 
ArrayTools v3.2 developed by Dr. Richard Simon and Amy Peng Lam 
(http://linus.nci.nih.gov/~brb/download.html). Basically, data was vigorously filtered to 
exclude control spots, empty spots, spots with high between-pixel-intensity variability 
and spots designated as bad by eye. Genes that had more than 25% missing data 
across all observations were excluded from the analysis. Genes significantly 
differentially expressed between the primary osteoblast cultures, and the 
osteosarcoma cell lines were identified by an F-test, using a randomised variance 
model and accounting for replicate readings of the same sample. Moreover, a 
multivariate permutation test (Reiner et al., 2003) was applied to account for a false 
discovery rate of only 10% in the set of significantly differentially expressed genes. 
Genes retained after filtering were hierarchically clustered by comparing their 
expression profiles across all samples by average linkage clustering. The robustness 
of the clustering results was tested by applying 100 independent perturbations of the 
data and re-clustering (McShane et al., 2002). 
For each osteosarcoma cell line, chromosomal regions with correlated gene 
expression were identified by CGH-miner 
(http://www-stat.stanford.edu/~wp57/CGH-Miner). Therefore, for each gene the 
signal intensity of each osteosarcoma cell line compared to the mean signal intensity 
of all primary osteoblast cultures was calculated and smoothed (moving average 
window of 5 genes) before the clustering along the individual chromosomes was 
applied. To determine whether chromosomal regions have similar co-expression 
across all osteosarcoma cell line samples, a false discovery rate of 1% was applied 
when compared to data of normal versus normal arrays (Wang et al., 2005).  
Overrepresentation of the selected genes in gene ontology categories (GO; 
http://www.geneontology.org) as compared to the entire filtered gene list was 
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analysed by EASE/DAVID version 2.0 (http://david.niaid.nih.gov/david/ease.html). 
Significant GO categories were identified based on the EASE score after Bonferroni 
correction for multiple testing (Hosack et al., 2003). Further functional analysis was 
performed by Pathway Assist 
(http://www.ariadnegenomics.com/products/pathway.html) through building and 
visualizing gene networks from our selected set of genes, based on a wide variety of 
biological data as collected with the automated text-mining program MedScan from 
PubMed and other public databases.  
 
Real-time RT-PCR  
 
For real-time Reverse Trancsriptase PCR (real-time RT-PCR), cDNA was generated 
by using Ready-To-GoTM You-Primed First-Strand Beads (Amersham Biosciences) 
and an oligo(dT) primer (Eurogentec) as described by the manufacturer. Primers 
were designed with the programme Primer Express (Applied Biosystems, Foster City, 
California, USA). These are shown in Table 1. Each RNA sample was analysed in 
triplicate in a final volume of 20 µl in a 384-well plate with the ABI Prism 7900 
Sequence Detection System (Applied Biosystems). Real-time RT-PCR data was 
analysed with the Sequence Detection System software (SDS 2.1.1, Applied 
Biosystems). For each gene the threshold cycle value (Ct) of every sample was 
extracted from the amplification plots. The difference in expression between 
osteosarcoma cell line samples and the primary osteoblast samples was determined 
for each gene using the ∆∆ median threshold cycle number (Ct) method. The 
corresponding fold change in expression was calculated by the formula 2-∆∆Ct (Livak 
and Schmittgen, 2001).  
Real-time RT-PCR data were statistically analysed using analysis of variance 
(ANOVA), including the β2-microglobulin gene as a covariate in the model. 
 
Table 1: Real-time RT-PCR primer sequences. 
Gene Forward primer Reverse primer Product size 
B2M TGACTTTGTCACAGCCCAAGATA AATGCGGCATCTTCAAACCT 79 bp 
WISP2 CACACAGCCTATATCAAACATGCA TAAGGGACTGCTTGTCCCATCT 83 bp 
PRIM1 GAAGAGCCCTTTTAGTGTTCATCCT AATGGATCAAACTGGTCCACTTTC 84 bp 
VCAM1 CATGGAATTCGAACCCAAACA GCTGACCAAGACGGTTGTATCTC 85 bp 
COL4A5 ACAGCTTTTGGCTGGCAACT CGGCTAATTCGTGTCCTCAAG 97 bp 
 
 




Expression profiling of primary osteoblasts and osteosarcoma cell lines 
 
Using 21K oligonucleotide micro-arrays, we performed gene expression profiling of 
cultures of five primary osteoblast isolates and five osteoblastic osteosarcoma cell 
lines in a randomised model. After filtering and normalisation the 10 samples were 
hierarchically clustered based on the transcriptional profile of the remaining 7,397 
genes. This showed a clear and consistent distinction between both classes of 
samples (Fig. 1). The dendrogram also shows that the variation between replicates of 




Figure 1: Hierarchical clustering tree of the expression profiles of 7,397 genes for cultures of five 
primary osteoblast specimens (POB) and of five different osteosarcoma cell lines. Each sample has 
been hybridised twice using different Cyanine fluorophores, G (Cy3) and R (Cy5). Correlations 





Two hundred and eighty six genes were significantly (P < 0.001) differentially 
expressed between the cultures of the primary osteoblast isolates and of the 
osteoblastic osteosarcoma cell lines. The 100 most significant differences 
represented 97 different genes of which 20 genes had a 2.8 to 6.8 fold 
overexpression in the osteosarcoma cell lines and 77 genes were higher expressed 
in primary osteoblasts with fold differences ranging from 2.7 to 66.7. The 10 most 
significantly higher expressed or lower expressed genes for the two classes, 
respectively, are listed in Table 2.  
 
Table 2: Ten most significantly differentially expressed genes in cultures of five osteosarcoma cell 
lines compared to cultures of five primary osteoblast specimens.  
 
GenBank Accession  Gene Symbol Gene Coding for Fold Difference 
Higher expressed    
AK026894 RHPN2 Rhopilin, Rho GTPase binding protein 2 6.8 
NM_033380 COL4A5 Collagen, type IV, alpha 5 (Alport syndrome) 6.2 
NM_000946 PRIM1 Primase, polypeptide 1, 49kDa 5.6 
NM_024094 DCC1 Defective in sister chromatid cohesion homolog 1 (S. 
cerevisiae) 
5.2 
BC010437 MGC22679 Hypothetical protein MGC22679 5.2 
NM_012198 GCA Grancalcin, EF-hand calcium binding protein 5.0 
NM_016623 FAM49B Family with sequence similarity 49, member B 5.0 
NM_014791 MELK Maternal embryonic leucine zipper kinase 4.3 
NM_004111 FEN1 Flap structure-specific endonuclease 1 4.2 
NM_014176 HSPC150 HSPC150 protein similar to ubiquitin-conjugating 
enzyme 
4.2 
    
Lower expressed    
NM_015429 ABI3BP ABI gene family, member 3 (NESH) binding protein 66.7 
NM_001078 VCAM1 Vascular cell adhesion molecule 1 47.6 
NM_003881 WISP2 WNT1 inducible signalling pathway protein 2 41.7 
NM_007281 SCRG1 Scrapie responsive protein 1 32.3 
NM_001353 AKR1C1 Aldo-keto reductase family 1, member C1 32.3 
NM_006475 POSTN Periostin, osteoblast-specific factor 26.3 
NM_032849 FLJ14834 Hypothetical protein FLJ14834 17.5 
NM_022842 CDCP1 CUB domain-containing protein 1 14.4 
NM_002427 MMP13 Matrix metalloproteinase 13 (collagenase 3) 13.9 
AK021531 COL3A1 Collagen, type III, alpha 1 13.2 
The selected genes are listed according to fold difference. 
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Several of the 286 genes are represented in the gene list by two independent 
oligonucleotides. Results for these pairs (Table 3) were concordant.  
 
Table 3: Consistency of differential gene expression as assessed by different oligonucleotides 
representing the same gene.  
 
Gene coding for GenBank Accession  Rank * Fold Difference ** 
Forkhead box C1 NM_001453 12 0.1 
 AK021858 13 0.1 
Phosphatase, orphan 2 BC010437 16 5.2 
 BC016950 31 5.0 
Collagen type VIII, alpha 1 AL359062 22 0.1 
 NM_001850 23 0.1 
ARG99 protein BC017984 123 0.2 
 AK055962 229 0.4 
UDP-N-acetyl-alpha-D-galatosamine AK024931 248 0.4 
 AK023815 265 0.4 
Dystonin AB018271 211 0.4 
 BC016991 239 0.2 
 NM_020388 NS 0.8 
Chromosome 5 open reading frame 13 AK021624 38 0.3 
 NM_004772 NS 0.4 
Lamin B2 M94362 58 2.2 
 NM_032737 NS 2.1 
Epithelial membrane protein 1 BC017854 89 0.1 
 NM_001423 NS 0.2 
ATPase, Class I, type 8B, member 2 AB032963 177 0.3 
 AK054886 NS 0.7 
* Rank is the ranking in the complete list of 286 significantly differentially expressed genes;  
NS indicates non-significant, meaning that the oligonucleotide does not occur in the list of 286 significantly 
differentially expressed genes.  
** Fold difference reflects the expression in osteosarcoma cell lines as compared to primary osteoblasts. 
 
Validation of micro-array expression data by real-time RT-PCR 
 
Two genes, COL4A5 and PRIM1, with a significantly higher expression in the 
osteosarcoma cell lines and two genes, VCAM1 and WISP2, with a significantly lower 
expression in the osteosarcoma cell lines, were assessed by real-time RT-PCR. After 
analysis of the PCR products in a 3% agarose gel, it was only in one cell line, SaOS-
2, that we did not observe a PCR product for one of these four genes, namely 
COL4A5. Therefore, the average level of mRNA expression of COL4A5 has been 
calculated over four osteosarcoma cell lines instead of five. COL4A5 and PRIM1 
were significantly higher expressed in the osteosarcoma cell lines with average fold 
changes of 28.2 (P < 0.05) and 9.6 (P < 0.00001), respectively. VCAM1 and WISP2 
were significantly (P < 0.00001) and very strongly lower expressed in osteosarcoma 






Figure 2: Gene expression differences between osteosarcoma cell lines and primary osteoblasts in 
culture. Expression level differences in mRNA between osteosarcoma cell lines (n = 5) and osteoblast 
isolates (n = 5) for the genes PRIM1, COL4A5, WISP2 and VCAM1 as determined by real-time 
RT-PCR are presented as the average fold difference (2-∆∆Ct) ± SEM after normalisation for 





Amongst the 286 differentially expressed genes, 184 genes had a functional 
annotation. Analysis of these 184 genes showed that genes encoding proteins 
associated with the cell membrane or the extracellular domain have generally a lower 
expression in osteosarcoma cell lines than in cultured osteoblasts. Genes coding for 
nuclear proteins are generally higher expressed in osteosarcoma cell lines (Table 4).  
 
Among the 97 most significantly differentially expressed genes, gene ontology (GO) 
annotation analysis showed a strong overrepresentation of genes belonging to the 
GO classes catalytic activity, binding, cell communication, cell adhesion and 
extracellular domain (data not shown).  
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Table 4: Functional classification of 184 genes with an annotation among the 286 differentially 
expressed genes.  
 






















  Membrane   Nucleus   
NM_001333 CTSL2 7.7 NM_012198 GCA 5.0 NM_004411 FEN1 4.2 
   AK021664 SLC24A5 4.0 NM_004153 ORCIL 3.8 
   NM_004233 CD83 2.7 NM_018365 MNS1 2.9 
   AB006624 KIAA0286 2.4 NM_024680 FLJ23311 3.7 
      NM_021927 FLJ13220 2.9 
      NM_002358 MAD2L 7.1 
      NM_014708 KNTC1 2.1 
      NM_022909 CENPH1 4.8 
      NM_004502 CDCA5 3.8 
      NM_001730 KLF5 5.6 
      NM_000946 PRIM1 5.6 
      NM_017955 CDCA4 3.1 
      NM_003090 SNRPA1 3.8 
      NM_000251 MSH2 4.5 
      NM_002266 KPNA1 3.1 
 






















  Membrane   Nucleus   
NM_001393 ECM2 6.4 AF380356 XG 5.9 X68742 PELO 4.5 
NM_014467 SRPX2 5.3 NM_002349 Ly75 5.8 AK027738 FOXP1 3.2 
NM_015424 CHL2 5.7 AK002171 FLJ11309 2.7 NM_119025 SMOX 3.3 
NM_000062 SERPING1 7.5 AB032963 ATP8B2 2.9 NM_021972 SPHK1 4.7 
AB021124 CHST2 5.6 BC017854 EMP1 12.3 AK021858 FOXC1 7.2 
NM_000396 CTSK 10.1 NM_005279 F2R 4.8 NM_005982 SIX1 3.3 
NM_007281 SCRG1 32.3 NM_002231 KAI1 5.1    
NM_000362 TIMP3 5.6 NM_031866 FZD8 4.5    
NM_006475 POSTN 26.3 NM_001078 VCAM1 47.6    
NM_003278 TNA 7.1 NM_014556 EVC 4.3    
NM_007036 ESM1 7.6 NM_054027 ANKH 4.3    
NM_001734 C1S 6.9 AF010236 SGCD 5.6    
NM_002009 FGF7 3.9 NM_033518 SLC38A5 5.3    
NM_000095 COMP 12.5 NM_007361 NID2 10.0    
NM_004750 CRLF1 12.4 NM_032812 PLXDC2 6.4    
NM_002402 MEST 11.9 AB006624 KIAA0286 0.4    
NM_031476 DKFZP434B044 4.8 NM_004791 ITGBL1 8.5    




Chromosomal regions with correlated expression 
 
In the individual osteosarcoma cell lines, several genomic regions showed co-
expression of genes (data not shown). We identified 7 regions in which genes, 
belonging to the 7,397 genes remaining after filtering, showed correlation in 
expression over all five osteosarcoma cell lines, i.e. 5q15, 9q22-q22.3, 11q22.2, 
17q21.2, 17q21.3, 17q24.2 and 20q12-q13.1. One of these regions, 17q21.3, 
showed an increased average expression of their genes, whereas the other 
chromosomal regions showed a decreased average expression of their genes in 
each of the osteosarcoma cell lines (Table 5). 
 
Table 5: Genomic regions with correlated gene expression changes across the osteosarcoma cell 







Gene Symbol  Gene coding for Average 
Expression 
5q15 NM_000439 PCSK1 Proprotein convertase subtilisin/kexin type 1 Lower 
 NM_001750 CAST Calpastatin  
9q22-q22.3 NM_017948 NOL8 Nucleolar protein 8 , Lower 
 NM_033014 OGN Osteoglycin (osteoinductive factor, mimecan)   
 NM_005014 OMD Osteomodulin,  
 NM_017680 ASPN Asporin (LRR class 1)  
 NM_001393 ECM2 Extracellular matrix protein 2  
 AK024267 FLJ1420 -  
 AB014599 KIAA0699 -  
11q22.2-q22.3 NM_002424 MMP8 Matrix metalloproteinase 8 (neutrophil collagenase) Lower 
 NM_002425 MMP10 Matrix metalloproteinase 10 (stromelysin 2)  
 NM_002421 MMP1 Matrix metalloproteinase 1 (interstitial collagenase)  
 NM_002422 MMP3 Matrix metalloproteinase 3 (stromelysin 1, progelatinase)  
 NM_002426 MMP12 Matrix metalloproteinase 12 (macrophage elastase)  
 NM_002427 MMP13 Matrix metalloproteinase 13 (collagenase 3)  
 NM_025208 PDGFD Platelet derived growth factor D   
17q21.2 NM_031959 KRTAP3-2 Keratin associated protein 3-2 Lower 
 NM_031957 KRTAP1-5 Keratin associated protein 1-5  
 NM_030966 KRTAP1-3 Keratin associated protein 1-3  
 NM_030967 KRTAP1-1 Keratin associated protein 1-1  
 BC012486 KRTAP2-1 Keratin associated protein 2-1  
17q21.3 NM_002145 HOXB2 Homeo box B2 Higher 
 AL137449 HOXB4 Homeo box B4  
 NM_002147 HOXB5 Homeo box B5  
 NM_018952 HOXB6 Homeo box B6  
 NM_004501 HOXB7 Homeo box B7  
17q24.2 NM_004694 SLC16A6 Solute carrier family 16 (monocarboxylic acid transporters), member 6 Lower 
 AK056789 FAM20A Family with sequence similarity 20, member A  
 NM_007168 ABCA8 ATP-binding cassette, subfamily A (ABC1), member 8  
20q12-q13.1 NM_003881 WISP2 WNT1 inducible signalling pathway protein 2 Lower 
 NM_022358 KCNK15 Potassium channel, subfamily K, member 15  
 




To increase our understanding of the molecular events that underlie osteosarcoma 
development, we wanted to identify genes differentially expressed between 
osteosarcoma and its progenitor cell, the osteoblast, by global gene expression 
profiling. In our study, osteosarcoma is represented by five independently established 
cell lines. As osteoblasts we used five different isolates from bone fragments, 
cultured for a single passage without any additional specific stimulation. The cells 
from these isolates were characterised as osteoblasts and could be clearly 
discriminated from fibroblasts, based on the expression profiles of six selected genes 
(M. Wilkens, K.A. Kooi, E.A.D. Plantinga, G.J. te Meerman, R.M.W. Hofstra, 
C.H.C.M. Buys, F. Gerbens, submitted). We expect that those genes that are 
differentially expressed between all five osteoblastic osteosarcoma cell lines and all 
five cultures of primary osteoblasts will include the genes involved in osteosarcoma 
development.  
Hierarchical clustering of vigorously filtered gene expression data showed a clear 
distinction between the expression profiles of the osteosarcoma cell lines and the 
cultured primary osteoblasts (Fig. 1). The distinction in gene expression between 
both sample groups appeared to be mainly caused by a set of 286 significantly 
differentially expressed genes. Micro-array based results were confirmed internally by 
results from different oligonucleotides on the array representing the same gene 
(Table 3) and by real-time RT-PCR results for PRIM1, COL4A5, WISP2 and VCAM1 
(Fig. 2). The observed differences between real-time RT-PCR and micro-array results 
for the genes WISP2 and VCAM1 are explained by pixel saturation of the spots on 
the micro-array resulting in an underestimation of the respective fold differences.  
For several genomic regions we found a higher or lower average expression of the 
genes in them, which may suggest that these regions are either affected by loss or 
gain of chromosomal regions or are subject to a common transcriptional regulation. 
Ozaki et al. (2003) have reported results of CGH analyses for four of our five 
osteosarcoma cell lines. Our findings did not show any clear correlation with those 
results. Analysis of chromosomal regions of co-expression for each cell line 
separately also did not show any association with the genomic aberrations reported 
by Ozaki et al. (2003) (data not shown). Therefore, common transcriptional regulation 
seems a likely explanation for at least part of our findings. 
Functional annotation based on MedScan (Pathway assist) was available for 184 of 
the 286 significantly differentially expressed genes. Many of these genes, encoding 
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proteins associated with the (glomerular) basement membrane and extracellular 
matrix, had a lower expression in the osteosarcoma cell lines, e.g. COL3A1, 
COL5A1, and COL8A1 encoding collagens; LAMA4 encoding laminin; NID2 
encoding nidogen; THBS1 and THBS3 encoding thrombospondins; CDH13 and 
PCDH18 encoding cadherins; and ITGBL1 and ITGA5 encoding integrins. MMP1, 
MMP3, MMP13 and MMP14, encoding matrix metalloproteinases, also had a lower 
expression in the osteosarcoma cell lines than in the cultured osteoblasts. 
Remarkably, TIMP3 encoding the MMP inhibitor was also lower expressed. The 
MMP gene cluster at 11q22.2-11q22.3 exhibited a strongly reduced average 
expression in all our osteosarcoma cell lines. This type of co-expression of MMP 
cluster genes has also been observed in normal breast tissue and breast tumours in 
contrast to several other tissues (Caron et al., 2001). Such tissue-specific co-
expression is another argument for common transcriptional regulation. Several other 
genes involved in maintaining the stability and organization of the extracellular 
matrix, such as TNFAIP6 had a lower expression in the osteosarcoma cell lines than 
in the osteoblast cultures. KRTAP1-1, KRTAP1-3, KRTAP1-5, KRTHA4 and KRT19, 
genes from the keratin-associated protein (KAP) gene cluster at 17q21.2, had also a 
lower expression in our osteosarcoma cell lines. This finding may be linked to the 
keratinocyte growth factor (FGF7) expression, which is significantly lower in the cell 
lines than in the cultured osteoblasts. Co-expression of this KAP cluster-containing 
region was also found in a large study of 130 breast carcinomas (Reyal et al., 2005). 
In general, results indicate that the basement membrane and extracellular matrix are 
less well-defined and organised in osteosarcoma cell lines than in osteoblasts. This 
has also been reported by others (Vaes et al., 2002; Thomas et al., 2004; Eppert et 
al., 2005) and may reflect the dedifferentiated state of osteosarcoma tumours and 
tumourigenic cells in general (Sato et al., 2005). Alternatively, it can reflect the 
altered environment for cells growing in vitro in specific cell culture media (Sandberg 
and Ernberg, 2005).  
Genes mainly associated with the cell nucleus and involved in cell cycle regulation 
and cell division, such as CDC7, CDC25C, CDCA8, PRIM1, RFC4, NUSAP1, 
HMGN3, RPA2, ECT2, PLK1, KIF22 and TOP2A, had a higher expression in the 
osteosarcoma cell lines, suggesting a higher proliferative activity of these cell lines. 
In addition, several genes involved in the initiation of replication (ORC1L, FOXC1), 
the regulation of the initiation of transcription (YEATS4, KLF5) and the mitotic spindle 
assembly checkpoint (MAD2L1, TTK, KIF2B, SPAG5) were higher expressed in the 
osteosarcoma cell lines. This may reflect an intrinsic tumour feature or may be the 
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result of positive selection during cell line establishment of cells with an enhanced 
proliferation capacity. In this respect, it may be noted that amplification of PRIM1, 
which gene initiates or primes DNA synthesis, has been found in 9 of 22 
osteosarcoma specimens tested (Yotov et al., 1999) and that PRIM1 maps close to 
CDK4, for which amplification has also frequently been found in osteosarcoma 
(Ladanyi et al., 1993a; Tarkkanen et al., 1995; Ragazzini et al., 1999). The cell 
division genes CDC7 and CDCA8 are both located at the short arm of chromosome 
1, an often amplified region in osteosarcoma (Mertens et al., 1993; Fletcher et al., 
1994; Zielenska et al., 2001; Ozaki et al., 2003; Atiye et al., 2005). Based on the 
analysis of chromosomal regions affected by gain or loss of expression, we found 
one cluster with a higher expression in the osteosarcoma cell lines, namely the 
HOXB gene cluster at 17q21.3. The core HOXB5, HOXB6 and HOXB7 genes and 
the flanking members had a higher expression in our osteosarcoma cell lines. In 
breast carcinoma cell lines as well as in tumours, the HOXB cluster has been 
identified as an amplicon with increases in gene expression related to the copy 
number (Hyman et al., 2002; Pollack et al., 2002; Reyal et al., 2005). In the 
osteosarcoma cell lines U-2 OS and SaOS-2, high-level gains were observed for the 
chromosomal region 17q22~qter by conventional-CGH analysis (Ozaki et al., 2003). 
The region 17q21.3 flanks 17q22-qter and might not be distinguishable from this 
latter region by conventional-CGH. 
Expression of several DNA repair-associated genes, namely BRCA2, EXO1, BARD1, 
KUB3, BLM, MSH2 and MSH6, is more prominent in the osteosarcoma cell lines than 
in primary cultured osteoblasts, suggesting an intensive DNA repair activity of the 
osteosarcoma cell lines, possibly associated with the higher proliferation. For cell 
lines in general, a higher expression of DNA repair-associated genes has also been 
described by Sandberg and Ernberg (2005).  
We found that a number of genes involved in the regulation of apoptosis or 
programmed cell death (CASP8, CASP9, TNFRS1B, FAF1, TRAF1 and TRIP) are 
affected in their expression. In contrast to our expectation that cell lines would have a 
repressed apoptotic programme, all pro-apoptotic proteins appeared to have an 
induced expression, whereas anti-apoptotic proteins were repressed in our 
osteosarcoma cell lines. CASP9, however, supposed to be involved in the caspase 
activation cascade, has a lower expression in osteosarcoma cell lines, thereby 
possibly dysregulating programmed cell death (Cardone et al., 1998). Each of the 
genomic regions for which we found correlated expression patterns have also been 
found in earlier studies on transcriptome analysis mainly focusing on breast cancer 
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tumours and cell lines (Caron et al., 2001; Hyman et al., 2002; Pollack et al., 2002; 
Reyal et al., 2005). Our results indicate that a similar co-expression of genes in these 
regions also occurs in osteosarcoma cell lines.  
An answer to the question whether the lower expression in osteosarcoma cell lines 
than in osteoblasts of genes encoding membrane-associated proteins and the higher 
expression of genes encoding nucleus-associated proteins should be considered as 
cell line-specific or tumour-specific, requires additional comparisons of gene 
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